Financials
Financial year 2025
Groupement Pharmaceutique de l'Union Européenne from Brussel, company number BE0468971838, closed financial year 2025 with a result of € -1,939 after tax. For that financial year Groupement Pharmaceutique de l'Union Européenne recorded a gross margin of € 562,251 and equity of € 1.8 million. Compared with financial year 2024, the result moved from € 110,714 to € -1,939. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.
€ 1.8 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1,939
▼ still € 110,714 profit in 2024
Profit after tax over the fiscal year.
€ 979,890
▼ 9% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
€ 518,257
▲ 2% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 26,486
▼ 12% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,389
▼ 73% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 112,029
▲ 51% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 607,194 | € 698,183 | € 670,824 | € 562,251 | ▼ 16% |
| Profit after taxes | € 81,513 | € 122,072 | € 110,714 | € -1,939 | ▼ € 112,653 |
| Equity | € 1,520,817 | € 1,642,889 | € 1,753,603 | € 1,751,663 | |
| Total debts | € 125,017 | € 101,175 | € 909,069 | € 942,257 | ▲ 4% |
| Cash | € 896,178 | € 999,019 | € 1,079,448 | € 979,890 | ▼ 9% |
| Land & buildings | € 708,234 | € 690,711 | € 673,188 | € 656,743 | ▼ 2% |
| Retained profit | € 967,861 | € 1,089,933 | € 1,200,646 | € 1,198,707 | |
| Balance sheet total | € 1,645,835 | € 1,744,064 | € 2,662,671 | € 2,693,921 | ▲ 1% |
| Employees (FTE) | 4.3 | 4.6 | 4.4 | - |
Key figures of Groupement Pharmaceutique de l'Union Européenne, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Groupement Pharmaceutique de l'Union Européenne?
What happened at Groupement Pharmaceutique de l'Union Européenne in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Apostolos Valtas stepped down as director. NBB
- Jesus Aguilar Santamaria stepped down as director. NBB
- Maria Teresa Moreira Da Cruz stepped down as director. NBB
- Ana Soldo stepped down as director. NBB
- Ly Rootslane stepped down as director. NBB
- Janusz Konstanty Mikolaj stepped down as director. NBB
- Clare Fitzell stepped down as director. NBB
- Mathias Steffen Arnold stepped down as director. NBB
In short
From € 81,513 profit in 2022 to € 1,939 loss in 2025.
Paid € 4,354 in corporate taxes since 2022.
Best year ever: 2023, with € 122,072 profit.
On average € 152,500 of value added per employee in 2024.
A new publication or filing at Groupement Pharmaceutique de l'Union Européenne? We notify you, reason included.
Follow Groupement Pharmaceutique de l'Union EuropéenneDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
Silviu Constantinescu
Director
since 2024 · until 2025
Claude Pfeiffer-Hosert
Director
since 2025 · until 2025
Apostolos Valtas
Director
since 2026 · until 2026
Jesus Aguilar Santamaria
Director
since 2026 · until 2026
Maria Teresa Moreira Da Cruz
Director
since 2026 · until 2026
Ana Soldo
Director
since 2026 · until 2026
Ly Rootslane
Director
since 2026 · until 2026
Janusz Konstanty Mikolaj
Chairman of the board
since 2026 · until 2026
Clare Fitzell
Director
since 2026 · until 2026
Mathias Steffen Arnold
Director
since 2026 · until 2026
Martin Kopecky
Director
since 2026 · until 2026
Dimitar Marinov
Director
since 2024 · until 2025
Establishments
Establishment units
Physical locations of this company
Luxemburgstraat 19-21
1000 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0468.971.838
- VAT number
- BE 0468.971.838
- Registered office
- Luxemburgstraat 19-21, 1000 Brussel
- Names & denominations
- Groupement Pharmaceutique de l'Union Européenne · GPEU
- Enterprise type
- Rechtspersoon
- Legal form
- International non-profit association
- Legal situation
- Normale toestand
- Start date
- 13 January 2000
- Peppol
- Active · Active since 12 Mar 2026
- Activities · NACE
Activiteiten van bedrijfs- en werkgeversorganisaties
Bedrijfs- en werkgeversorganisaties
Activiteiten van beroepsorganisaties
Beroepsorganisaties